12.20.19
4 min. read

Summing up the Prescription Digital Therapeutics Worldview

Issue 032. Get E&O weekly. | Subscribe | Digital health research from Brian Dolan.

Welcome to E&O.

Last week's newsletter had a 64 percent open rate. Here's what's happening this week:

  • Keeping this brief as we draw to the end of the year: Read on for a dozen thoughts on Prescription Digital Therapeutics in 2019.

Did this get forwarded to you? You can sign up as a paying subscriber and get full access to E&O by clicking this --> You're making the right decision.

A dozen thoughts on Prescription Digital Therapeutics in 2019

What follows is a collection of notes, lessons learned, and commonly held opinions from those working in prescription digital therapeutics. Most of these come from conversations I've had with readers over the past few months, weeks, and days.

What's missing?

  • Prescription digital therapeutics (PDTs) are a new therapeutic modality -- just as there were small

Paying Subscribers Only

It's a good one, too.
This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!
×

Recent Articles